BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23928243)

  • 1. Breast magnetic resonance imaging for monitoring response to therapy.
    Ojeda-Fournier H; de Guzman J; Hylton N
    Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):533-46. PubMed ID: 23928243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
    Schott AF; Roubidoux MA; Helvie MA; Hayes DF; Kleer CG; Newman LA; Pierce LJ; Griffith KA; Murray S; Hunt KA; Paramagul C; Baker LH
    Breast Cancer Res Treat; 2005 Aug; 92(3):231-8. PubMed ID: 16155794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
    Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
    J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance spectroscopy of the breast: current status.
    Bolan PJ
    Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):625-39. PubMed ID: 23928249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
    Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
    Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
    Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
    Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Drucker MJ; Livingston RB
    Cancer; 1999 Jun; 85(11):2410-23. PubMed ID: 10357412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?
    Heldahl MG; Lundgren S; Jensen LR; Gribbestad IS; Bathen TF
    J Magn Reson Imaging; 2011 Sep; 34(3):547-56. PubMed ID: 21761463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy.
    Takeda K; Kanao S; Okada T; Kataoka M; Ueno T; Toi M; Ishiguro H; Mikami Y; Togashi K
    Eur J Radiol; 2012 Oct; 81(10):2627-31. PubMed ID: 22221829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?
    Wu LM; Hu JN; Gu HY; Hua J; Chen J; Xu JR
    Breast Cancer Res Treat; 2012 Aug; 135(1):17-28. PubMed ID: 22476850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy in the treatment of breast cancer.
    Redden MH; Fuhrman GM
    Surg Clin North Am; 2013 Apr; 93(2):493-9. PubMed ID: 23464698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
    Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
    Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
    Kim R; Osaki A; Toge T
    Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.